Gerald W. Bruce Appointed President and CEO of Novvae Pharmaceuticals

Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that Gerald W. Bruce has been appointed as President and CEO of Novvae Pharmaceuticals, Virpax’s wholly-owned subsidiary focused solely on advancing the Company’s OTC pipeline.

Mr. Bruce has spent over 30 years in the pharmaceutical and medical nutrition industries. Most recently, he served as a Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division. Prior to this position, he has held roles of increasing responsibility at Nitromed, Inc. and Bristol-Meyers Squibb. Mr. Bruce began his career at Johnson and Johnson and spent 13 years there starting as a sales representative and moving up the ranks to become a Group Marketing Director in Analgesics. He has a BA from Lincoln University and an Executive Master’s Degree in Leadership from Georgetown University’s McDonough School of Business.

“Gerald, with his background in the pharma and medical nutrition industries, is uniquely positioned to lead Novvae. His experience and knowledge of the OTC market will be beneficial to us as we advance AnQlar as well as add new nonprescription product candidates that will utilize our novel delivery technologies,” commented Anthony P. Mack, Chairman and CEO of Virpax.

About Novvae Pharmaceuticals

Novvae Pharmaceuticals, a wholly-owned subsidiary of Virpax Pharmaceuticals, is developing over-the-counter (OTC) products using innovative metered-dose drug delivery platforms. Novvae is seeking approval of AnQlar which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights to NobrXiol. Virpax has competitive cooperative research and development agreements (CRADAs) for all three of its prescription drug candidates, two with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Novvae Pharmaceuticals, a wholly-owned subsidiary of Virpax, is developing over-the-counter (OTC) products using innovative metered-dose drug delivery platforms. Novvae is seeking approval of AnQlar which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2.For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.